Abstract

CHORENO PARRA, José Alberto  and  GUADARRAMA ORTIZ, Parménides. Genetically modified T lymphocytes: A new hope for glioblastoma treatment?. Rev. Fac. Med. (Méx.) [online]. 2019, vol.62, n.5, pp.7-10.  Epub Jan 12, 2021. ISSN 2448-4865.  https://doi.org/10.22201/fm.24484865e.2019.62.5.02.

Glioblastoma is among the most aggressive primary tumors of the central nervous system due to its high capacity to acquire resistance to many of the currently available oncologic treatments. Likewise, this tumor possesses an elevated potential for recurrence generating a high mortality among affected individuals. Therefore, there is an urgent necessity for new therapeutic strategies to achieve a higher remission rate and a better survival rate in patients with glioblastoma. New advances in immunotherapy, such as the production of autologous T lymphocytes modified by genetic engineering, are promissory therapeutic agents capable of providing a considerable degree of control over different types of cancers. In this article, we discuss the results of some recent studies

Keywords : CAR T cells; glioblastoma; immunotherapy; brain tumors; cancer.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )